Clinical trial · Observational
Observational Study on Patients With Hepatocellular Carcinoma (HCC)
NCT04021056CI-TRIAL-00039494unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an ongoing, longitudinal, single centre, observational, retro-prospective clinical cohort study of patients with HCC in usual clinical practice. All the HCC patients diagnosed and treated in Liver Cancer Center, Nanfang Hospital are consecutively collected and followed up.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Evaluate the overall survival rate of all HCC patients
- timeFrame
- 10 years
- description
- In order to identify the potential influence factors of HCC patients survival
- measure
- Evaluate the recurrence free survival rate of HCC patients after curative treatments
- timeFrame
- 10 years
- description
- In order to identify the potential influence factors of tumor recurrence
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnosis of HCC; * Age ≥ 16 years; * Received treatment targeting for HCC at least once, including operation, ablation, TACE, sorafenib, radiotherapy, chemotherapy, etc; * Good compliance with clinical treatment. Exclusion Criteria: * Diagnosed as other pathological types such as cholangiocarcinoma, or mixed liver cancer; * Received only traditional Chinese medicine or symptomatic supportive treatment; (3) survival time ≤ 7 days; * HCC diagnosed after liver transplantation; * Poor compliance or important data deficient.
References
Publications (0)
Data not yet available
No reference posted for this study.